FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients.

被引：0
|
作者：
Neuzillet, C.
Hentic, O.
Rousseau, B.
Rebours, V.
Bengrine-Lefevre, L.
Bonnetain, F.
Raymond, E.
Ruszniewski, P.
Louvet, C.
Hammel, P.
机构：
[1] Hop Beaujon, Clichy La Garenne, France
[2] Hop St Antoine, F-75571 Paris, France
[3] Ctr Georges Francois Leclerc, Dijon, France
[4] Beaujon Univ Hosp, Clichy, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4132
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma
    Amal Rayan
    Ola N. Abdel Fattah
    Ahmed Soliman
    Hosam A. Hasan
    Asmaa M. Zahran
    Journal of Gastrointestinal Cancer, 2019, 50 : 519 - 524
  • [32] Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma
    Rayan, Amal
    Fattah, Ola N. Abdel
    Soliman, Ahmed
    Hasan, Hosam A.
    Zahran, Asmaa M.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (03) : 519 - 524
  • [33] Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
    Morgensztern, D
    Lim, WT
    Subramanian, J
    Viswanathan, A
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 694S - 694S
  • [34] Clinical Impact of Oral Intake in Second-line or Third-line Chemotherapy for 589 Patients With Advanced Gastric Cancer A Retrospective Cohort Study
    Ogata, Takatsugu
    Narita, Yukiya
    Kumanishi, Ryosuke
    Nakazawa, Taiko
    Matsubara, Yuki
    Kato, Kyoko
    Nozawa, Kazuki
    Honda, Kazunori
    Masuishi, Toshiki
    Bando, Hideaki
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (08): : 388 - 394
  • [35] The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer
    Boeck, Stefan
    Heinemann, Volker
    FUTURE ONCOLOGY, 2008, 4 (01) : 41 - 50
  • [36] Selective Intra-arterial Chemotherapy with Floxuridine as Second- or Third-Line Approach in Patients with Unresectable Colorectal Liver Metastases
    Samaras, Panagiotis
    Breitenstein, S.
    Haile, S. R.
    Stenner-Liewen, F.
    Heinrich, S.
    Feilchenfeldt, J.
    Renner, C.
    Knuth, A.
    Pestalozzi, B. C.
    Clavien, P. A.
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (07) : 1924 - 1931
  • [37] Selective Intra-arterial Chemotherapy with Floxuridine as Second- or Third-Line Approach in Patients with Unresectable Colorectal Liver Metastases
    Panagiotis Samaras
    S. Breitenstein
    S. R. Haile
    F. Stenner-Liewen
    S. Heinrich
    J. Feilchenfeldt
    C. Renner
    A. Knuth
    B. C. Pestalozzi
    P. A. Clavien
    Annals of Surgical Oncology, 2011, 18 : 1924 - 1931
  • [38] Algorithm for identifying various second- and third-line chemotherapy regimens in elderly US Medicare patients with metastatic colon cancer
    Bikov, Kaloyan A.
    Mullins, C. Daniel
    Onukwugha, Ebere
    Seal, Brian S.
    Hanna, Nader
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [39] ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer - A phase II multicenter trial
    Schulz, J
    Keller, A
    Canfield, V
    Parker, G
    Douglass, E
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (04): : 337 - 342
  • [40] A multi-center retrospective analysis of patients with relapsed/refractory follicular lymphoma after third-line chemotherapy
    Fuji, Shigeo
    Tada, Yuma
    Nozaki, Kenji
    Saito, Hideaki
    Ozawa, Takayuki
    Kida, Toru
    Kosugi, Satoru
    Sugahara, Hiroyuki
    Ikeda, Hirokazu
    Hashimoto, Koji
    Karasuno, Takahiro
    Ueda, Shuji
    Ishikawa, Jun
    Shibayama, Hirohiko
    ANNALS OF HEMATOLOGY, 2020, 99 (09) : 2133 - 2139
12345